Or Eisenberg Email

Chief Financial Officer . NeuroSense Therapeutics

Cambridge, MA

Location

Current Roles

Employees:
28
Revenue:
$0
About
Advancing research, development and therapy for ALS and additional CNS indications.\n\nNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.\n\nCurrently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.\n$NRSN
NeuroSense Therapeutics Address

Cambridge, MA
il
NeuroSense Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.